Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety... Show more
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AUGP | 34.01 | 0.01 | +0.03% |
| PGIM S&P 500 Buffer 12 ETF - August (AUGP) | |||
| IQSM | 38.44 | N/A | N/A |
| NYLIM Candriam U.S. Mid Cap Equity ETF (IQSM) | |||
| ILS | 20.14 | -0.02 | -0.10% |
| Brookmont Catastrophic Bond ETF | |||
| DVDN | 13.79 | -0.08 | -0.60% |
| Kingsbarn Dividend Opportunity ETF (DVDN) | |||
| DGS | 62.41 | -0.77 | -1.22% |
| WisdomTree Emerging Markets SmallCap Dividend Fund (DGS) | |||
A.I.dvisor indicates that over the last year, CING has been loosely correlated with CTMX. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if CING jumps, then CTMX could also see price increases.
| Ticker / NAME | Correlation To CING | 1D Price Change % | ||
|---|---|---|---|---|
| CING | 100% | -4.04% | ||
| CTMX - CING | 35% Loosely correlated | -3.31% | ||
| ELVN - CING | 29% Poorly correlated | +0.81% | ||
| PLX - CING | 28% Poorly correlated | -2.90% | ||
| TGTX - CING | 27% Poorly correlated | -3.87% | ||
| SABS - CING | 27% Poorly correlated | -3.47% | ||
More | ||||
CING saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on August 31, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In 43 of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The 10-day RSI Indicator for CING moved out of overbought territory on August 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In 15 of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at 79%.
The Momentum Indicator moved below the 0 level on September 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CING as a result. In 74 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
CING moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CING crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CING declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CING entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 59 of 63 cases where CING's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
Following a +2.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where CING advanced for three days, in 188 of 223 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
CING may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.987) is normal, around the industry mean (26.780). P/E Ratio (0.024) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. CING’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CING’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.